Intellia Therapeutics (NTLA) Accumulated Depreciation (2015 - 2025)

Intellia Therapeutics (NTLA) has 11 years of Accumulated Depreciation data on file, last reported at $58.6 million in Q4 2025.

• On a quarterly basis, Accumulated Depreciation rose 17.94% year-over-year to $58.6 million in Q4 2025; TTM through Dec 2025 was $58.6 million, a 17.94% increase from a year earlier, with the FY2025 full-year figure at $58.6 million, up 17.94% from the prior year.
• Accumulated Depreciation for Q4 2025 stood at $58.6 million, up from $49.7 million in the prior quarter.
• Over the last five years, Accumulated Depreciation for NTLA reached as high as $58.6 million in Q4 2025 and fell as low as $26.1 million in Q4 2021.
• Historically, Accumulated Depreciation has averaged $41.5 million across 5 years, with a median of $39.9 million in 2023.
• Across the five-year window, Accumulated Depreciation surged 35.09% in 2021 and grew 17.94% in 2025, its largest moves.
• Year by year, Accumulated Depreciation stood at $26.1 million in 2021, then increased by 27.13% to $33.2 million in 2022, then increased by 20.07% to $39.9 million in 2023, then increased by 24.66% to $49.7 million in 2024, then rose by 17.94% to $58.6 million in 2025.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $58.6 million in Q4 2025, $49.7 million in Q4 2024, and $39.9 million in Q4 2023.